86 research outputs found
standard and innovation
Die akute lymphoblastische LeukÀmie im Kindesalter hat mit heutigen Methoden
eine Heilungsrate von ĂŒber 90%. Dagegen ĂŒberleben nur etwa 50% der Kinder mit
RĂŒckfall einer ALL trotz intensiver Chemotherapie und HSZT bei den meisten
Patienten. Somit besteht bei Kindern mit ALL-Rezidiv ein dringender Bedarf fĂŒr
die weitere Optimierung der Standardtherapie, der besseren Charakterisierung
von biologischen und prognostischen Subgruppen sowie fĂŒr neue Medikamente mit
anderen idealerweise gezielteren Wirkmechanismen, die in der Lage sind,
Therapieresistenz der leukÀmischen Klone zu durchbrechen. Die ALL-REZ BFM
Studiengruppe hat seit nunmehr 30 Jahren Therapieoptimierungsstudien
durchgefĂŒhrt und damit die Prognose der Kinder mit ALL-Rezidiv konsequent
verbessert. Dabei wurde insbesondere die Dosierung und der Verabreichungsmodus
von hoch dosiertem Methotrexat in prospektiven randomisierten Studien
untersucht, wobei in der Studie ALL-REZ BFM 90 die Dosis von 1g/mÂČ mit einer
Infusionsdauer von 36 und einer reduzierten Leukovorin Rescue als optimales
Konzept etabliert werden konnten. Neben den randomisierten Fragen konnte diese
Studie eine Reihe weiterer Erkenntnisse ĂŒber die biologische Charakteristik
der Erkrankung, prognostische Faktoren und Therapieverbesserungen im
historischen Vergleich erarbeiten. Die intensive Chemotherapie und die
allogene hÀmatopoetische Stammzelltransplantation ist verbunden mit akuten
Nebenwirkungen und SpÀtfolgen zu denen auch das Auftreten von Zweitmalignomen
gehört. Im Verlauf der ALL-REZ BFM Studien konnten Patientengruppen definiert
werden, die eine besonders schlechte Prognose haben und mit konventioneller
Therapie nicht heilbar sind. Zu diesen zÀhlen Patienten mit Rezidiv von
lymphoblastischen Lymphomen, sowie Patienten mit Nonresponse auf die
konventionelle Rezidiv- Induktionstherapie. Innovative diagnostische Verfahren
erlauben darĂŒber hinaus, weitere Patientengruppen zu definieren, die ein hohes
Folgerezidivrisiko trotz intensiver konventioneller Therapie haben. Dazu zÀhlt
die Quantifizierung minimaler Resterkrankung im Therapieverlauf durch
molekularbiologische Methoden. Insbesondere Patienten mit einer hohen
minimalen Resterkrankung vor allogener hÀmatopoetischer
Stammzelltransplantation haben ein hohes Risiko fĂŒr ein erneutes ALL-Rezidiv
mit dann infauster Prognose. Die so definierten Patientengruppen haben neben
solchen mit Folgerezidiv einer ALL einen dringenden Bedarf fĂŒr die EinfĂŒhrung
von neuen Substanzen mit anderen Wirkmechanismen als die der konventionellen
Chemotherapie und idealerweise mit gezielter leukÀmiespezifischer AktivitÀt
und geringeren akuten und langfristigen Nebenwirkungen. Die ALL-REZ BFM
Studiengruppe beteiligt sich an einem Programm zur Entwicklung von neuen
Substanzen bei ALL im Kindesalter, das eine enge Interaktion mit den
zustÀndigen Behörden, der pharmazeutischen Industrie und den involvierten
akademischen Gruppen erfordert. Die zukĂŒnftigen Strategien zur Behandlung von
Kindern mit rezidivierter und/oder refraktÀrer ALL werden in einem durch die
EU finanziertes Projekt international harmonisiert und erlauben die
DurchfĂŒhrung von prospektiven randomisierten Studien in biologischen
Subgruppen, um neue Substanzen nach erfolgreichen Phase I/II Studien in
kurative Therapiekonzepte integrieren zu können. Die aus dieser Entwicklung
erwachsene Vision ist eine nebenwirkungsarme gezielte und individualisierte
Behandlung von Kindern mit ALL mit möglichst vollstÀndiger Vermeidung von
RĂŒckfĂ€llen der Erkrankung.Todayâs cure rates of childhood acute lymphoblastic leukemia (ALL) have
exceeded 90%. In contrast, only 50% of children with relapsed ALL survive
despite intensive chemotherapy and allogeneic hematopoietic stem-cell
Transplantation (HSCT) in most patients. Thus, there is an urgent need for
optimization of standard therapy in childhood relapsed ALL, for a better
characterization of biologic and prognostic subgroups, and for new drugs with
ideally targeted mechanism of action allowing for overcoming treatment
resistance of leukemic clones. The ALL-REZ BFM Study Group has conducted
clinical trials for optimization of treatment since 30 years and subsequently
improved the prognosis of children with relapsed ALL. In particular the dose
and mode of application of high dose methotrexate has been investigated in
randomized prospective trials. Furthermore, improvement of therapy has been
achieved with uncontrolled changes referring to historical controls. Intensive
chemotherapy and allogeneic HSCT is associated with acute and late toxicities
one of which is secondary malignancy. In the course of the ALL-REZ BFM trials
patient subgroups could be defined with a very poor prognosis and without
chance of cure with conventional therapies. These include patient with relapse
of a lymphoblastic lymphoma and those with nonresponse to conventional salvage
induction therapy. The quantification of minimal residual disease (MRD) with
molecular biologic techniques allow defining additional patient groups with
very high risk for subsequent relapse despite intensive conventional
treatment. Those patients with high MRD pre allogeneic HSCT have a high risk
of relapse post HSCT with then dismal prognosis. These patient groups have an
urgent need for the introduction of new drugs with targeted mechanism of
action and less acute and late side effects. The ALL-REZ BFM Study Group joins
activities to develop such new agents in close collaboration with industry and
competent authorities. Future strategies for treatment of childhood relapsed
ALL in Europe are harmonized in an EU funded FP7 project allowing for
performing large prospective randomized trials in biologic subgroups to
integrate new agents after successfully passing phase I/II trials in curative
treatment protocols. The vision for the future is a low-toxic individualized
treatment for children with ALL with prevention of relapse of the disease
Total body irradiation as part of conditioning regimens in childhood leukemiaâlong-term outcome, toxicity, and secondary malignancies
Background: Total body irradiation (TBI) is an established part of conditioning regimens prior to stem cell transplantation in childhood leukemia but is associated with long-term toxicity. We retrospectively analyzed survival, long-term toxicity, and secondary malignancies in a pooled cohort of pediatric patients (pts.) treated with the same TBI regimen.
Methods: Analyzed were 109 pts. treated between September 1996 and November 2015. Conditioning treatment according to EBMT guidelines and the ALL SCTped 2012 FORUM trial consisted of chemotherapy (CT) and TBI with 2 Gy b.i.d. on 3 consecutive days to a total dose of 12 Gy. Median follow-up was 97.9 months (2-228 months).
Results: Overall survival (OS) in our cohort at 2, 5, and 10 years was 86.1, 75.5, and 63.0%, respectively. Median survival was not reached. Long-term toxicity developed in 47 pts. After chronically abnormal liver and kidney parameters in 31 and 7 pts., respectively, growth retardation was the most frequent finding as seen in 13 pts. Secondary malignancies were rare (n = 3).
Conclusion: TBI-containing conditioning regimens in pediatric stem cell transplantation (SCT) are highly effective. Efforts to replace TBI- with CT-containing regimens have only been successful in subgroups of pts. Although we could show long-term toxicity in 43% of pts., overall survival was 63% at 10 years. Still, long-term effects such as growth retardation can permanently impact the pts.' quality of life and functioning. Along with new substances, efforts should be undertaken to optimize TBI techniques and accompany the treatment by systematic follow-up programs beyond 5 years to improve detection of rare events
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma
Despite improved outcomes achieved in the last decades for children with newly diagnosed leukaemia and lymphoma, treatment of patients with refractory/relapsed disease remains a challenge. The cure rate is still unsatisfactory and often achieved at the cost of significant morbidity. Exploring treatment with novel agents should offer less toxic therapeutic options, without compromising efficacy. Bispecific and antibody-drug conjugates targeting CD19 and CD22 (blinatumomab and inotuzumab ozogamicin) play an important role in the treatment of relapsed and refractory B-cell precursor acute lymphoblastic leukaemia (BCP-ALL); antibodies targeting CD123 and CD38 are also under investigation for acute myeloid leukaemia (AML) and T-ALL, respectively. Targeted therapy with small molecules is of primary importance for specific genetic subtypes, such as BCR-ABL-positive ALL, FLT3-ITD AMLÂ and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. KMT2A-directed targeted therapy with menin inhibitors holds promise to be of relevance in KMT2A-rearranged leukaemias, known to have dismal prognosis. Target inhibition in cellular pathways such as BCL-2, RAS, MEK, Bruton's tyrosine kinase, JAK-STAT or CDK4/CDK6 inhibition may be suitable for different diseases with common mutated pathways. Nevertheless, development and approval of new agents for paediatric cancers lags behind adult therapeutic options. New regulations were implemented to accelerate drug development for children. Considering the number of oncology medicinal products available for adults and the rarity of paediatric cancers, prioritisation based on scientific evidence and medical need, as well as international collaboration, is critical. Herein, we review the current status of drug development for children with leukaemia and lymphoma, excluding cellular therapy despite its well-known significance
Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Following Blinatumomab-Induced Remission in Pediatric Patients with Relapsed/Refractory (r/r) B-Precursor Acute Lymphoblastic Leukemia (ALL): Preliminary Results from a Phase I/II Stud
n/
Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
n/
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study
Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) accounts for âŒ25% of pediatric malignancies. Of interest, the incidence of ALL is observed âŒ20% higher in males relative to females. The mechanism behind the phenomenon of sex-specific differences is presently not understood. Employing genome-wide genetic aberration screening in 19 ALL samples, one of the most recurrent lesions identified was monoallelic deletion of the 5âČ region of SLX4IP. We characterized this deletion by conventional molecular genetic techniques and analyzed its interrelationships with biological and clinical characteristics using specimens and data from 993 pediatric patients enrolled into trial AIEOP-BFM ALL 2000. Deletion of SLX4IP was detected in âŒ30% of patients. Breakpoints within SLX4IP were defined to recurrent positions and revealed junctions with typical characteristics of illegitimate V(D)J-mediated recombination. In initial and validation analyses, SLX4IP deletions were significantly associated with male gender and ETV6/RUNX1-rearranged ALL (both overall P < 0.0001). For mechanistic validation, a second recurrent deletion affecting TAL1 and caused by the same molecular mechanism was analyzed in 1149 T-cell ALL patients. Validating a differential role by sex of illegitimate V(D)J-mediated recombination at the TAL1 locus, 128 out of 1149 T-cell ALL samples bore a deletion and males were significantly more often affected (P = 0.002). The repeatedly detected association of SLX4IP deletion with male sex and the extension of the sex bias to deletion of the TAL1 locus suggest that differential illegitimate V(D)J-mediated recombination events at specific loci may contribute to the consistent observation of higher incidence rates of childhood ALL in boys compared with girl
Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age
While survival has improved for Burkitt lymphoma patients, potential differences in outcome between pediatric and adult patients remain unclear. In both age groups, survival remains poor at relapse. Therefore, we conducted a comparative study in a large pediatric cohort, including 191 cases and 97 samples from adults. While TP53 and CCND3 mutation frequencies are not age related, samples from pediatric patients showed a higher frequency of mutations in ID3, DDX3X, ARID1A and SMARCA4, while several genes such as BCL2 and YY1AP1 are almost exclusively mutated in adult patients. An unbiased analysis reveals a transition of the mutational profile between 25 and 40 years of age. Survival analysis in the pediatric cohort confirms that TP53 mutations are significantly associated with higher incidence of relapse (25â±â4% versus 6â±â2%, p-value 0.0002). This identifies a promising molecular marker for relapse incidence in pediatric BL which will be used in future clinical trials
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
Drug sensitivity and resistance testing on diagnostic leukemia samples should provide important functional information to guide actionable target and biomarker discovery. We provide proof of concept data by profiling 60 drugs on 68 acute lymphoblastic leukemia (ALL) samples mostly from resistant disease in cocultures of bone marrow stromal cells. Patient-derived xenografts retained the original pattern of mutations found in the matched patient material. Stromal coculture did not prevent leukemia cell cycle activity, but a specific sensitivity profile to cell cycle-related drugs identified samples with higher cell proliferation both in vitro and in vivo as leukemia xenografts. In patients with refractory relapses, individual patterns of marked drug resistance and exceptional responses to new agents of immediate clinical relevance were detected. The BCL2inhibitor venetoclax was highly active below 10 nM in B-cell precursor ALL (BCP-ALL) subsets, including MLL-AF4 and TCF3-HLF ALL, and in some T-cell ALLs (T-ALLs), predicting in vivo activity as a single agent and in combination with dexamethasone and vincristine. Unexpected sensitivity to dasatinib with half maximal inhibitory concentration values below 20 nM was detected in 2 independent T-ALL cohorts, which correlated with similar cytotoxic activity of the SRC inhibitor KX2-391 and inhibition of SRC phosphorylation. A patient with refractory T-ALL was treated with dasatinib on the basis of drug profiling information and achieved a 5-month remission. Thus, drug profiling captures disease-relevant features and unexpected sensitivity to relevant drugs, which warrants further exploration of this functional assay in the context of clinical trials to develop drug repurposing strategies for patients with urgent medical needs.Peer reviewe
- âŠ